Cerebrospinal Fluid Aβ Levels Correlate With Structural Brain Changes in Parkinson's Disease.

Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
Movement Disorders (Impact Factor: 5.68). 03/2013; 28(3). DOI: 10.1002/mds.25282
Source: PubMed


ParkWest is a large Norwegian multicenter study of newly diagnosed drug-naïve subjects with Parkinson's disease (PD). Cognitively normal PD subjects (PDCN) and PD subjects with mild cognitive impairment (PDMCI) from this cohort have significant hippocampal atrophy and ventricular enlargement, compared to normal controls. Here, we aimed to investigate whether the same structural changes are associated with cerebrospinal fluid (CSF) levels of amyloid beta (Aβ)(38) , Aβ(40) , Aβ(42) , total tau (t-tau), and phosphorylated tau (p-tau). We performed three-dimensional radial distance analyses of the hippocampi and lateral ventricles using the MRI data from ParkWest subjects who provided CSF at baseline. Our sample consisted of 73 PDCN and 18 PDMCI subjects. We found significant associations between levels of all three CSF Aβ analytes and t-tau and lateral ventricular enlargement in the pooled sample. In the PDCN sample, all three amyloid analytes showed significant associations with the radial distance of the occipital and frontal horns of the lateral ventricles. CSF Aβ(38) and Aβ(42) showed negative associations, with enlargement in occipital and frontal horns of the lateral ventricles in the pooled sample, and a negative association with the occipital horns in PDMCI. CSF Aβ levels in early PD correlate with ventricular enlargement, previously associated with PD dementia. Therefore, CSF and MRI markers may help identify PD patients at high risk for developing cognitive decline and dementia in the course of their illness. Contrary to Alzheimer's disease, we found no associations between CSF t-tau and p-tau and hippocampal atrophy. © 2013 Movement Disorder Society.

Download full-text


Available from: Johanne Somme
  • Source
    • "Although BCHE K+ |APOE ␧4+ individuals may be more likely to develop DLB than PDD, carriers of these alleles with PD are more likely to develop dementia at an earlier age and stage of their movement disorder [34]. While loss of dopamine neurotransmission and cortical ␣-synuclein pathology may contribute to cognitive impairment and dementia, PD patients with the highest burden of cortical A␤ plaques and/or lowest levels of CSF A␤ 42 have the fastest progression of cognitive (but not motor) decline, incident dementia, and Alzheimer-like structural brain changes [83] [84] [85] [86]. These patients also have highest CSF levels of ApoE [87]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cholinesterase enzymes metabolize acetylcholine (ACh). Inhibition of acetylcholinesterase (AChE) in damaged but functional cholinergic synapses in the brains of dementia patients increases intrasynaptic ACh. This enhances cholinergic neurotransmission and improves cognition. There is a window of opportunity for this symptomatic treatment effect that opens and closes during the course of dementia depending on when significant synaptic damage occurs. Cholinesterases also metabolize extrasynaptic ACh with butyrylcholinesterase (BuChE) apparently playing the major dynamic role in extracellular ACh homeostasis. Extracellular ACh plays a key regulatory role in controlling the reactivity and functional states of non-excitable cells, such as neuroglia. Current inhibitors of cholinesterases (ChEIs) have similar effects on intrasynaptic ACh, but differ markedly in abilities to upregulate extracellular AChE, inhibit BuChE, and influence the fibrilization of amyloid-β peptides. Importantly, ChEIs can have detrimental disease modifying effects in particular individuals characterized by age, gender, and genotype. In contrast, preliminary evidence suggests that the right dose of the right ChEI in the right patient might significantly slow the progression of neurodegenerative processes. For a particular patient, understanding the condition of cholinergic synapses and the reactivity and functional status of neuroglia could allow administration of appropriate ChEI therapy for symptomatic and disease modifying benefits.
    Full-text · Article · Nov 2014 · Journal of Alzheimer's disease: JAD
  • Source
    • "Because there is much evidence on the contribution of oxidative stress in the pathogenesis of PD (Figure 1) (Alonso-Navarro et al., 2008), the measurement of oxidative stress markers and substances related with oxidative and defense against oxidative phenomena in the CSF of PD patients is useful. Data regarding lipid peroxidation markers are controversial, while DNA oxidation markers have been found to be increased (Table 3). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The blood-brain barrier supplies brain tissues with nutrients and filters certain compounds from the brain back to the bloodstream. In several neurodegenerative diseases, including Parkinson's disease (PD), there are disruptions of the blood-brain barrier. Cerebrospinal fluid (CSF) has been widely investigated in PD and in other parkinsonian syndromes with the aim of establishing useful biomarkers for an accurate differential diagnosis among these syndromes. This review article summarizes the studies reported on CSF levels of many potential biomarkers of PD. The most consistent findings are: (a) the possible role of CSF urate on the progression of the disease; (b) the possible relations of CSF total tau and phosphotau protein with the progression of PD and with the preservation of cognitive function in PD patients; (c) the possible value of CSF beta-amyloid 1-42 as a useful marker of further cognitive decline in PD patients, and (d) the potential usefulness of CSF neurofilament (NFL) protein levels in the differential diagnosis between PD and other parkinsonian syndromes. Future multicentric, longitudinal, prospective studies with long-term follow-up and neuropathological confirmation would be useful in establishing appropriate biomarkers for PD.
    Full-text · Article · Nov 2014 · Frontiers in Cellular Neuroscience
  • Source
    • "The findings of current study indicate increased ventricular size in the brain of mice treated with MPTP. Larger ventricular size is one of the indicators of cognitive impairment in late Parkinson's subjects (Lewis et al. 2009; Dalaker et al. 2011; Beyer et al. 2013). The finding of increased ventricular size with MPTP exposure suggests progression of PD in mice in line with the sporadic PD. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In this study, we have evaluated cerebral atrophy, neurometabolite homeostasis, and neural energetics in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridin (MPTP) model of Parkinson's disease. In addition, the efficacy of acute l-DOPA treatment for the reversal of altered metabolic functions was also evaluated. Cerebral atrophy and neurochemical profile were monitored in vivo using MRI and 1H MR Spectroscopy. Cerebral energetics was studied by 1H-[13C]-NMR spectroscopy in conjunction with infusion of 13C labeled [1,6-13C2]glucose or [2-13C]acetate. MPTP treatment led to reduction in paw grip strength and increased level of GABA and myo-inositol in striatum and olfactory bulb. 13C Labeling of glutamate-C4 (1.93 ± 0.24 vs. 1.48 ± 0.06 μmol/g), GABA-C2 (0.24 ± 0.04 vs. 0.18 ± 0.02 μmol/g) and glutamaine-C4 (0.26 ± 0.04 vs. 0.20 ± 0.04 μmol/g) from [1,6-13C2]glucose was found to be decreased with MPTP exposure in striatum as well as in other brain regions. However, glutamine-C4 labeling from [2-13C]acetate was found to be increased in the striatum of the MPTP-treated mice. Acute l-DOPA treatment failed to normalize the increased ventricular size and level of metabolites but recovered the paw grip strength and 13C labeling of amino acids from [1,6-13C2]glucose and [2-13C]acetate in MPTP-treated mice. These data indicate that brain energy metabolism is impaired in Parkinson's disease and acute l-DOPA therapy could temporarily recover the cerebral metabolism. Cerebral atrophy, neurometabolite homeostasis, and neural energetics have been evaluated in an MPTP model of Parkinson's disease using MRI, in vivo 1H MRS and 1H-[13C]-NMR spectroscopy, respectively. MPTP treatment led to reduced paw grip strength and neuronal function. Acute Levodopa treatment was able to recover the diminished motor function and cerebral function. CMRGlc, Cerebral metabolic rate of glucose oxidation; MPTP, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridin.
    Full-text · Article · Aug 2013 · Journal of Neurochemistry
Show more